Bavarian Nordic
Bavarian Nordic is a leading industrial biotechnology company
developing and producing novel vaccines for the treatment and
prevention of life-threatening diseases with a large unmet medical
need. The company's business strategy is focused in three areas:
biodefence, cancer and infectious diseases.
With operations in Denmark, Germany, the USA, and Singapore,
Bavarian Nordic employs over 350 people.
Bavarian Nordic's patented technology, MVA-BN®, is as been
demonstrated in clinical studies, one of the world's safest,
multivalent vaccine vectors for the development of vaccines against
various infectious diseases such as smallpox, HIV/AIDS, as well as
against breast and prostate cancer. Several MVA-BN®-based HIV,
cancer and smallpox vaccines are in clinical Phase I and Phase II
trials.
Bavarian Nordic has ongoing development contracts with the US
government (awarded in June 2007*, September 2004** and February
2003) to develop IMVAMUNE® as a safe third-generation smallpox
vaccine. Bavarian Nordic's advanced clinical development programme
has been further expedited by the US government with the FDA's
grant of "fast-track" status for IMVAMUNE®, the first-ever
smallpox vaccine candidate to be given this designation.
